Disease |
Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
prostate cancer |
N/A |
N/A |
N/A |
regulation |
Oncogene |
24373479 |
LncRNADisease
|
prostate cancer |
N/A |
N/A |
N/A |
regulation |
The prostate cancer-associated ncRNA transcript 1 lncRNA PCAT1, SchlAP1 (second chromosome locus associated with prostate-1), and CTBP1-AS indicate cancer cell invasiveness and metastasis in prostate cancer progression. |
24531795 |
LncRNADisease
|
polycystic ovary syndrome |
N/A |
N/A |
N/A |
N/A |
C-Terminal binding protein 1 antisense (CTBP1-AS) was a novel long noncoding RNA (lncRNA) to regulate AR activity. Expression level of CTBP1-AS in peripheral blood leukocytes was significantly higher in women with PCOS than that in controls after adjustment for age and body mass index (BMI). |
25552498 |
LncRNADisease
|
prostate cancer |
qPCR, Western bolt, Northern bolt, RIP etc. |
prostate cancer tissue, cell lines (VCaP, LNCaP, DU145, RWPE etc.) |
up-regulated |
N/A |
CTBP1-AS is predominantly localized in the nucleus and its expression is generally upregulated in prostate cancer. CTBP1-AS promotes both hormone-dependent and castration-resistant tumour growth. Mechanistically, CTBP1-AS directly represses CTBP1 expression by recruiting the RNA-binding transcriptional repressor PSF together with histone deacetylases. CTBP1-AS also exhibits global androgen-dependent functions by inhibiting tumour-suppressor genes via the PSF-dependent mechanism thus promoting cell cycle progression. |
23644382 |
Lnc2Cancer
|
hepatocellular carcinoma |
RT-qPCR |
serum |
N/A |
N/A |
high sensitivity and specificity for discriminating HCC from healthy controls and also from CHC patients |
27113935 |
|
chronic hepatitis C |
RT-qPCR |
serum |
N/A |
N/A |
high sensitivity and specificity for discriminating HCC from healthy controls and also from CHC patients |
27113935 |
|
|